



European Society For Medical
Oncology (ESMO) 2025

Post-Conference Survey

Are you interested to hear what
Healthcare Professionals were
most interested in?

Swipe to see the results



Most surveyed attended ESMO 2025 in person

65%

Attended in-person in Berlin

VS.

24%

Logged in remotely to live sessions

50%

Read summary information

Such as abstracts, in lieu of watching live or archived sessions

37%

Watched archived sessions


39%

Followed sessions via social media

*How did you engage in the ESMO Congress 2025?
Select all that apply.*

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.

Educational, Presidential Sessions & Scientific Congress Highlights had highest engagement



How would you describe your level of engagement in each of the following types of sessions held during the ESMO Congress 2025? Top 2 selection (6-7), 'extremely engaging'. Rating question: scale 1 to 7 where 1 is 'Not Engaged at all/ did not attend' and 7 is 'extremely engaging'.

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.

AstraZeneca and Daiichi-Sankyo generated the most excitement at ESMO 2025



Which companies do you feel generated the biggest 'buzz' at ESMO 2025?
Rank the top 3.

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.



Generated the biggest buzz due to pivotal trial data across tumours

1

Standout data across multiple tumours

2

Leadership in next-gen modalities and innovative pipeline

3

High-quality engagement and meeting presence

Why do you say [insert company from previous question that ranked 1] generated the biggest 'buzz'? Please be as specific as possible.

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.


AstraZeneca also provided the best experience overall to HCPs at ESMO 2025



Which companies do you feel provided the best experience overall at ESMO 2025?
Rank the top 3.

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.

Breast Cancer results have the greatest potential to shape clinical practice



In your opinion, treatment of which tumor/malignancy types are most likely to change based on data presented at ESMO 2025? Please rank the top 3 therapy areas likely to change following data presented at ESMO

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.

Most exciting abstract/data readouts were
in MIBC, Breast and NSCLC...

KEYNOTE-905/EV-303

DESTINY-Breast05

DESTINY-Breast11

ASCENT-03

FLAURA2

Based on information you reviewed at ESMO 2025, provide names and/or descriptions of up to 3 abstracts or data readouts that you found most exciting or practice changing: (Open ended answer box)

Source: Adelphi Research, post-ESMO online global study n=100 HCPs.

Let's grow your brand

*Build brand knowledge
Don't just measure it*

**Stand out in a crowded market
with an insight-driven strategy**

»»» *Real time insights
from HCPs at major
global congresses*

»»» *Bespoke Oncology
research positioning
your brand for
long-term success*

Elevate your oncology story today with

Pam.Hallworth@omc.com

